Life company versus CMBS for a long hold with possible sales

A loan can produce less cash when one property is sold and still have a lower total financing cost over the remaining hold. A life-company versus CMBS comparison should separate release principal, transaction expense, and the interest on the debt that remains. Treating every dollar withheld at a partial sale as a fee gives the wrong answer.

This article uses two invented portfolio loans, each assumed to permit a particular partial release under negotiated conditions. No release right, price, or prepayment mechanism should be inferred from the provider’s category.

Establish the release event before comparing rates

Suppose an owner expects to hold a portfolio for ten years but may sell one property at the end of year four. Both proposals fund $10 million, remain interest only, and mature at the end of year ten. All payments are made as scheduled, with no default. The retained properties and their operating results are identical under both loans.

If nothing is sold early, ten years of interest plus the initial fees total $6.6 million for L and $6.4 million for C. Principal payoff is excluded from financing expense but remains a cash obligation. C has a $200,000 nominal expense advantage in this simplified no-sale case.

Provider labels do not settle flexibility. MetLife Investment Management’s mortgage page describes varied structures and explicitly qualifies its lending guidelines as illustrative. A particular insurer-related offer still needs its own release language.

Build a partial-sale settlement rather than a penalty percentage

Assume the property sells at year four for $5 million, with $200,000 of selling costs common to both proposals. That leaves $4.8 million before the loan’s release requirements.

For this hypothetical comparison, L requires $3 million of principal repayment and $60,000 of release-related expense. C requires $3.6 million of principal reduction and $180,000 of all-in release-related expense. The latter is an assumed specialist-quoted transaction cost, not a calculated defeasance price or a universal CMBS fee.

C produces $720,000 less cash at the sale. Only $120,000 of that difference is additional transaction expense. The other $600,000 retires additional debt and reduces subsequent interest and final payoff. It cannot be counted as both a fee and a principal benefit later.

If the owner needs $1.5 million from this sale to fund a separate committed project, L meets that use and C leaves a $480,000 gap. That financing constraint can matter even if C has a lower total nominal cost over ten years. The owner should identify whether replacement liquidity is actually available and what it costs.

Continue the calculation after the release

For the first four years, C saves $100,000 of interest relative to L. After its additional $50,000 initial fee, it has saved $50,000 before the sale. Its additional $120,000 release expense then makes cumulative financing expense $70,000 higher at that point.

After the release, L’s annual interest is $455,000 on $7 million. C’s is $400,000 on $6.4 million. Across the remaining six years, C saves $330,000 of interest.

The complete ten-year financing-expense comparison for the partial-sale path is:

C now has a $260,000 nominal expense advantage over the full period despite releasing less cash at year four. This is not a discounted return ranking. It excludes the value or cost of having $720,000 less available at that intermediate date, taxes, earnings on retained liquidity, and any new borrowing required to replace it.

Prove the release is permitted before relying on the table

Obtain the actual release clause, allocated loan amount, required payment calculation, remaining collateral tests, timing restrictions, notice period, and consent process. Determine who supplies the binding calculation and which assumptions can move before settlement. Counsel and the appropriate specialist should resolve the governing language.

CMBS can involve several servicing and transaction roles. The historical Benchmark 2025-B41 Form 8-K, Item 8.01 identifies master servicers, special servicers, and other participants. It does not establish who may approve this hypothetical release or promise that a different loan allows one. Use the executed agreement and current servicing instructions to identify the decision route.

Apply the same discipline to L. An origination contact’s willingness to discuss a sale is not a contractual release right. If one proposal cannot release the selected property, replace its table with the cost and feasibility of the actual alternative, such as full repayment. Do not keep comparing an unavailable partial-sale path.

Preserve both economic and liquidity conclusions

Report total financing expense, owner cash at the sale, remaining principal, and any replacement-capital requirement separately. A single blended cost number obscures the timing decision. If the sale date changes, rebuild both the accrued interest and release quote for that date rather than moving the old numbers one column to the right.

For the owner with the $1.5 million year-four need, L has an immediate funding advantage. For an owner without that obligation, C’s lower long-hold financing expense may deserve more weight. Neither conclusion follows from “life company” or “CMBS” alone; it follows from a documented release path and the owner’s use of the cash it produces.